MYC and colorectal carcinoma: In particular, as a next step in our research program, we plan to screen a large cohort of paired normal and CRC samples for c-MYC K158/K163Me levels and correlate c-MYC methylation with key clinical outcomes, such as survival rates and treatment response, in order to validate it as a clinical biomarker.